FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Manufacturer

Country

Certificates

FDA

Document

No Title 0.18 MB
No Title 0.18 MB
Registration Date 11 Nov 2014
Share

DaunoXome®

Medicine Pharmaceuticals Product Number : 10885-001-01

Antineoplastic Agent

Drug Information

Generic
DAUNORUBICIN CITRATE LIPOSOMAL
NDC Code
10885-001-01
Drug Class
Anthracycline Topoisomerase Inhibitor
Therapeutic Class
Antineoplastic
Dosage form
Solution
Route of Administration
Intravenous Injection
Therapeutic Area
1.Kaposi’s sarcoma

Indication

First line cytotoxic therapy for advanced HIV-associated Kaposi's sarcoma.

Benefit

To maximize tumor targeting further, the DaunoXome liposomes are filtered so the particles are within the 35-nm-to-65-nm range; tumor blood vessels have increased permeability to particles in this range. Another important benefit of this formulation is that it can be used concurrently with the more commonly prescribed antiretrovival agents without increased risk.